Skip to main content
Premium Trial:

Request an Annual Quote

Lipomics to Help Isis Pharma Test Compounds for Metabolic Drug Trials

NEW YORK (GenomeWeb News) — Lipomics today said it will provide its lipid metabolite services to Isis Pharmaceuticals.
 
Under the terms of the agreement, Lipomics will support Isis in its pre-clinical and clinical trials of lipid compounds that may be used to treat metabolic diseases.
 
Lipomics said it will hold exclusive rights to develop diagnostics that result from the research, while Isis will retain rights to therapeutics.
 
Lipomics’ model “focuses on providing plasma-based mechanistic markers of lipid metabolism,” said president and CSO Steve Watkins.
 
Financial terms of the agreement were not released.
 
On Monday, Lipomics said it signed an agreement to use Agilent Technologies’ biomarker-based assays for its metabolic analytical research.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.